Skip to main content

Advertisement

SpringerLink
Log in

Therapy of isolated locoregional recurrent carcinoma of the breast

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

There is widespread consent that isolated locoregional recurrence (ILRR) in breast cancer should be treated surgically. On searching literature and guidelines most studies include ipsilateral recurrence in breast tissue or on thoracic wall post-mastectomy, recurrence in scar tissue as well as in ipsilateral axillary lymph nodes. Some studies discuss metachronous contralateral breast cancer as ILRR. About 10–35% of women with primary breast cancer suffer from ILRR. The existing data concerning the role of systemic therapy in the treatment of ILRR are insufficient. We investigated the influence of chemotherapy on disease-free- (DFS) and overall-survival (OS).

Methods

Retrospective analysis of all patients with ILRR and without distant metastasis was done, which were treated at the Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University between 2005 and 2013. Data collection used patients’ database system and was followed via patient questionnaires.

Results

In total, we collected data of 93 patients with locally recurrent breast cancer and observed a 72.6% questionnaire response rate. Average timeline accounted for 99 months between primary diagnosis and local recurrence; average age of patients at diagnosis of local recurrence was 60.6 years. After a median follow-up of 63 months DFS reached 76% with and 73% without chemotherapy, and after 74 months overall survival amounted to 94% and 70%, respectively.

Conclusion

Almost all patients with ILRR were operated. Especially patients with hormone receptor-negative recurrent breast cancer seemed to show a benefit having been treated with chemotherapy. Most patients were without recurrence after their particular therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Aebi S, Gelber S, Anderson SJ, Láng I, Martín M et al (2014) Chemotherapy for isolated locoregional recurrence of breast cancer: the CALOR randomised trial. Lancet Oncol. 15(2):156–163. https://doi.org/10.1016/S1470-2045(13)70589-8.Chemotherapy

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bayerl A, Frank D, Lenz A, Höß C, Lukas P, Feldmann HJ, Molls M (2001) Lokale Tumorkontrolle und kosmetisches Ergebnis nach brusterhaltender Operation und Strahlentherapie bis 56 Gy Gesamtdosis ohne Boost beim Mammakarzinom. Strahlenther Onkol 1:25–32. https://doi.org/10.1007/s00066-001-0811-9

    Article  Google Scholar 

  3. Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F et al (2011) Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 459(1):1–10. https://doi.org/10.1007/s00428-011-1097-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E (2012) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(SUPPL. 7):10. https://doi.org/10.1093/annonc/mds232

    Article  Google Scholar 

  5. Clemons M, Danson S, Hamilton T, Goss P (2001) Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev 27:67–82. https://doi.org/10.1053/ctr

    Article  CAS  PubMed  Google Scholar 

  6. Clemons M, Hamilton T, Mansi J, Lockwood G, Goss P (2003) Management of recurrent locoregional breast cancer: oncologist survey. Breast 9776:328–337. https://doi.org/10.1016/S0960-9776(03)00107-3

    Article  Google Scholar 

  7. Gluck S (2010) Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. Am J Clin Oncol 33(3):314–319. https://doi.org/10.1097/COC.0b013e31819fdf9b

    Article  CAS  PubMed  Google Scholar 

  8. Gräßer J (2007) Mögliche Einflüsse auf die Rezidiventwicklung beim Mammakarzinom und Vergleich der Methoden zur Diagnostik von Primärtumor und Rezidiv. München: Dissertation Ludwig-Maximilians-Universität

  9. Hannoun-Levi J, Resch A, Gal J, Kauer-dorner D, Strnad V (2013) Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol 108(2):226–231. https://doi.org/10.1016/j.radonc.2013.03.026

    Article  PubMed  Google Scholar 

  10. Harms W, Krempien R, Hensley FW, Berns C, Wannenmacher M, Fritz P (2001) Results of chest wall reirradiation using pulsed-dose-rate (PDR) brachytherapy molds for breast cancer local recurrences. Int J Radiat Oncol Biol Phys 49(1):205–210. https://doi.org/10.1016/S0360-3016(00)01360-2

    Article  CAS  PubMed  Google Scholar 

  11. Insa A, Lluch A, Prosper F, Marugan I, Martinez-agullo A, Garcia-conde J (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56:67–78

    Article  CAS  PubMed  Google Scholar 

  12. Janssen S, Rades D, Meyer A, Fahlbusch FB, Wildfang I, Meier A et al (2018) Local recurrence of breast cancer: conventionally fractionated partial external beam re-irradiation with curative intention. Strahlenther Onkol 194(9):806–814. https://doi.org/10.1007/s00066-018-1315-1

    Article  CAS  PubMed  Google Scholar 

  13. Kraus-Tiefenbacher U, Bauer L, Scheda A, Schoeber C, Schaefer J, Steil V, Wenz F (2007) Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy. BMC Cancer 7:1–7. https://doi.org/10.1186/1471-2407-7-178

    Article  Google Scholar 

  14. Liedtke C, Jackisch C, Thill M, Thomssen C, Müller V, Janni W (2018) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2018. Breast Care 13(3):196–208. https://doi.org/10.1159/000489329

    Article  PubMed  PubMed Central  Google Scholar 

  15. Mavrova R, Radosa J, Schmitt K (2014) Estrogen, progesterone, and her-2/neu receptor expression discrepancy in primary tumors and in-breast relapse in patients with breast cancer. Breast J. https://doi.org/10.1111/tbj.12270

    Article  PubMed  Google Scholar 

  16. MD Anderson Cancer Center (2018) Breast cancer—invasive. https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/cancer-treatment/ca-treatment-breast-invasive-web-algorithm.pdf. Accessed 28 Dec 2018

  17. Melchior P, Hayo C, Knobe S, Rübe C, Solomayer EF, Juhasz-Böss I, Breitbach GP (2018) Postoperative alleinige Teilbrustbestrahlung mittels interstitieller Multikatheter-Brachytherapie bei ipsilateralen Rezidiven des Mammakarzinoms nach brusterhaltender Operation und vorangegangener perkutaner Strahlentherapie. Senologie—Zeitschrift für Mammadiagnostik und -therapie 15(02):32–33. https://doi.org/10.1055/s-0038-1651761

    Article  Google Scholar 

  18. Moossdorff M, Van Roozendaal LM, Strobbe LJA, Aebi S, Cameron DA, Dixon JM et al (2014) Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. J Natl Cancer Inst 106(12):1–7. https://doi.org/10.1093/jnci/dju288

    Article  Google Scholar 

  19. Prystash YY (2017) Features of the immunohistochemical characteristics of primary tumors and recurrences of breast cancer after radical treatment. Wiadomosci Lekarskie (Warsaw, Poland : 1960) 70(2):227–230

    Google Scholar 

  20. Pusztai L, Viale G, Kelly CM, Hudis CA (2010) Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 15(11):1164–1168. https://doi.org/10.1634/theoncologist.2010-0059

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rauschecker H, Clarke M, Gatzemeier W, Recht A (2001) Systemic therapy for treating locoregional recurrence in women with breast cancer (Review). Cochrane Library. https://doi.org/10.1002/14651858.CD002195 (https://www.cochranelibrary.com)

    Article  Google Scholar 

  22. Rubino C, Arriagada R, Delaloge S, Lê MG (2010) Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer 102(1):213–219. https://doi.org/10.1038/sj.bjc.6605434

    Article  CAS  PubMed  Google Scholar 

  23. Waeber M, Castiglione-Gertsch M, Dietrich D, Thurlimann B, Goldhirsch A, Brunner KW, Borner MM (2003) Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 14(8):1215–1221

    Article  CAS  PubMed  Google Scholar 

  24. Wapnir IL, Gelber S, Anderson SJ, Mamounas EP, Robidoux A, Martin M, Nortier JWR, Geyer CE, Paterson AHG et al (2017) Poor prognosis after second locoregional recurrences in the CALOR trial. Ann Surg Oncol. 24(2):398–406. https://doi.org/10.1245/s10434-016-5571-y

    Article  PubMed  Google Scholar 

  25. Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martin M, Nortier JWR et al (2018) Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial. J Clin Oncol 36(11):1073–1079. https://doi.org/10.1200/JCO.2017.76.5719

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Woeckel A, Kreienberg R, Janni W, Brust K (2017) Interdisziplinäre S3-Leitlinie für die Früherkennung, Nachsorge des Mammakarzinoms. 2017. Retrieved from Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)

  27. Yang Y-F, Liao Y-Y, Yang M, Peng N-F, Xie S-R, Xie Y-F (2014) Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients. Med Oncol (Northwood Lond Engl) 31(10):214. https://doi.org/10.1007/s12032-014-0214-2

    Article  CAS  Google Scholar 

  28. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM et al (2013) Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata. J Clin Oncol 31(17):2128–2135. https://doi.org/10.1200/JCO.2012.43.7251

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Yoon TI, Lee JW, Lee SB, Sohn G, Kim J, Chung IY et al (2018) No association of positive superficial and/or deep margins with local recurrence in invasive breast cancer treated with breast-conserving surgery. Cancer Res Treat 50(1):275–282. https://doi.org/10.4143/crt.2017.041

    Article  PubMed  Google Scholar 

Download references

Funding

This study was not funded.

Author information

Authors and Affiliations

  1. Department of Gynecology, Obstetrics and Reproductive Medicine, University Hospital Medical School, Kirrbergerstraße 100, 66421, Homburg/Saar, Germany

    Lena Gabriel, Marina Schmidt, Stephanie Juhasz-Böss, Anika von Heesen, Gilda Schmidt, Erich-Franz Solomayer, Ingolf Juhasz-Böss & Georg-Peter Breitbach

  2. Department for Oncology and Hematology, University Hospital Medical School, Homburg, Germany

    Nicole Kranzhöfer

  3. Department of Radiation Oncology, University Hospital Medical School, Homburg, Germany

    Patrick Melchior

Authors
  1. Lena Gabriel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marina Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephanie Juhasz-Böss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick Melchior
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anika von Heesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gilda Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nicole Kranzhöfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Erich-Franz Solomayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ingolf Juhasz-Böss
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Georg-Peter Breitbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LG: data analysis, manuscript writing. MS: data collection and analysis, manuscript writing. SJ-B: protocol development and data collection. PM: radiotherapeutic protocol development, data analysis, manuscript review. AvH: surgical data collection. G Schmidt: surgical data collection. NK: systemic therapy data collection and analysis. EFS: manuscript editing. IJ-B: project development, data analysis, manuscript review and editing. GPB: data analysis, manuscript writing, review and editing.

Corresponding author

Correspondence to Georg-Peter Breitbach.

Ethics declarations

Conflict of interest

Authors Lena Gabriel, Marina Schmidt, Stephanie Juhasz-Böss, Patrick Melchior, Anika von Heesen, Gilda Schmidt, Nicole Kranzhöfer, Erich-Franz Solomayer, Ingolf Juhasz-Böss and Georg-Peter Breitbach declare that he/she has no conflict of interest.

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gabriel, L., Schmidt, M., Juhasz-Böss, S. et al. Therapy of isolated locoregional recurrent carcinoma of the breast. Arch Gynecol Obstet 300, 365–376 (2019). https://doi.org/10.1007/s00404-019-05220-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-019-05220-x

Keywords

Search

Navigation